Skip to content
Screener

Discontinued — last reported Q2 '24

EPS (Diluted) at other companies

Bausch Health Companies logo
Bausch Health CompaniesBHC
-$3.82-2,287%
Artivion logo
ArtivionAORT
-$0.28-1,033%
AIR
AirSculpt Technologies, Inc.AIRS
-$0.02-100%
AngioDynamics logo
AngioDynamicsANGO
-$0.27-80.0%
PROCEPT BioRobotics Corporation logo
PROCEPT BioRobotics CorporationPRCT
-$0.47-34.3%
AtriCure logo
AtriCureATRC
$0.18+238%

Other financials

Income statement

See full
Revenue$12.5M+32.4%
Gross profit$7.5M-19.2%
Operating income-$5.5M-349%
Net income-$2.1M+48.6%

Balance sheet

See full
Cash & equivalents$31.1M+0.4%
Total debt$39.5M+1.4%
Total equity$12.8M+22.1%
Total assets$63.0M+4.8%

Cash flow

See full
Operating cash flow-$572.0K+18.5%
CapEx$60.0K+9.1%
Free cash flow-$632.0K+16.5%

Valuation

See full
Market cap$128.48M+71.6%
Enterprise value$136.8M+61.6%
P/S2.3×+0.7×

Profitability

See full
Gross margin61.9%-3.1pp
Operating margin-46%+9.9pp
Net margin-16.2%-6.2pp
FCF margin-16.1%-4.8pp

Returns & leverage

See full
Return on equity-77.8%-22.4pp
Debt / equity3.1×-0.6×
Current ratio5.8×+0.3×

Where this comes from

Reported directly by Apyx Medical Corporation in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Apyx Medical Corporation’s 10-Q, filed August 8, 2024.

Filed
Aug 8, 2024
Fiscal quarter
Q2 FY2024
Calendar quarter
Q2 2024
Accession
0000719135-24-000038
Line itemThree Months Ended June 30, 2024Three Months Ended June 30, 2023Six Months Ended June 30, 2024Six Months Ended June 30, 2023
Total other (expense) income, net(989)282(1,911)94
Loss before income taxes(6,536)(953)(14,073)(6,752)
Income tax expense (benefit)5066103(2,201)
Net loss(6,586)(1,019)(14,176)(4,551)
Net loss attributable to non-controlling interest(30)(25)(44)(74)
Net loss attributable to stockholders$(6,556)$(994)$(14,132)$(4,477)
Loss per share:
Basic and diluted$(0.19)$(0.03)$(0.41)$(0.13)

Item 1. Financial Statements

FAQ

What is Apyx Medical Corporation's EPS (diluted)?
Apyx Medical Corporation (APYX) reported EPS (diluted) of -$0.19 in Q2 2024.
How has Apyx Medical Corporation's EPS (diluted) changed year-over-year?
Apyx Medical Corporation's EPS (diluted) decreased by 533.3% year-over-year, from -$0.03 to -$0.19.
What is the long-term trend for Apyx Medical Corporation's EPS (diluted)?
Over 2 years (2021 to 2023), Apyx Medical Corporation's EPS (diluted) has grown at a 10.8% compound annual growth rate (CAGR), from -$0.44 to -$0.54.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Apyx Medical Corporation's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude